AllDocs -> cancers

Ovarian Cancer Canada 1 Ovarian cancer in Canada 2,500 The number of women newly diagnosed with ovarian cancer each year. 1,500 The number of women who die of ovarian cancer each year. 4 The ranking of ovarian cancer for potential years of life lost due to cancer in women. 80-90 The percentage of women with low-stage disease diagnosis who survive at least five years. 20 The percentage of women with low-stage disease diagnosis. 80 The percentage of women with high-stage disease diagnosis. 5-30 The percentage of women with high-stage disease diagnosis who survive at least five years. 5-15 The percentage of ovarian cancers attributed to inherited genetic mutations. Frustration led to determination In ...

This document is provided to you by the American College of Radiology. We strive to deliver this information in a convenient and effective manner. After you finish reviewing the criteria, please provide us with valuable feedback by taking a four-question survey . American College Of Radiology ACR Appropriateness Criteria™ OVARIAN CANCER SCREENING Expert Panel on Women’s Imaging: Marcela Böhm-Vélez, MD 1 ; Ellen Mendelson, MD 2 ; Robert Bree, MD 3 ; Harris Finberg, MD 4 ; Elliot K. Fishman, MD 5 ; Hedvig Hricak, MD, PhD 6 ; Faye Laing, MD 7 ; David Sartoris, MD 8 ; Amy Thurmond, MD 9 ; Steven Goldstein, MD 10 . Summary of Literature Review Ovarian cancer is the most frequent cause of death from gynecologic ...

Frequently Asked Questions about Ovarian Cancer What is ovarian cancer ? Cancer is a disease in which certain body cells don’t function right, divide very fast, and produce too much tissue that forms a tumor. Ovarian cancer is cancer in the ovaries, the female reproductive organs located in the pelvis. The ovaries make female hormones and store eggs that, if fertilized by sperm, can develop into a baby. Women have two ovaries, one on each side of the uterus. Tumors found in the ovaries may be non-cancerous tissue growths (cysts) or cancerous growths that may spread to other parts of the body. Why should I be concerned about ovarian cancer ? About 1 in every 57 women in the United States will develop ovarian cancer . Most cases occur in women over the age of 50, but this disease can also affect younger women. Ovarian cancer causes more deaths ...

ovarian cancer Ovarian Cancer Ron Swensen, M.D. Extent of the Problem 23,000 cases annually 15,900 deaths annually 4th most common cause of cancer mortality among American women Most (70%) diagnosed at advanced stage where cure is uncommon Presenting Symptoms Often called the “silent killer” NOCN says that it “whispers” Ask Barbara Goff, she has a research interest in this question. Women surveyed before laparotomy for pelvic mass compared with women surveyed in a primary care clinic Ovarian Cancer Symptoms Ovarian Cancer Symptoms These symptoms were usually of SHORTER duration than controls Implying a more acute onset Symptoms were usually more intense than controls Hard to quantify on an individual basis ...

ovarian cancer Best Practice for ovarian cancer : Guidelines for the management of women with epithelial ovarian cancer Dr Margaret Davy AM Chair Guidelines Working Party Who was involved in the guideline development? November 2000 Multidisciplinary working party formed Sponsored by Australian Cancer Network Sept 2001 Ovarian Cancer Program federally funded and under umbrella NBCC Extensive collaboration with all interested groups and individuals Why develop guidelines? Ovarian cancer is a significant cause of mortality for Australian women No guidelines available for clinicians Provide evidence-based recommendations for best practice RAISE AWARENESS of clinicians and women Current practice problems No set patterns of care Many people treating ...

REPORT OF THE NATIONAL OVARIAN CANCER FORUM Ovarian cancer : health service delivery supporting best practice Monday 16 th February 2004 Dockside Function Centre Cockle Bay Wharf Darling Park, Sydney, NSW G G y y n n a a e e c c o o l l o o g g i i c c a a l l C C a a n n c c e e r r R R e e s s e e a a r r c c h h F F u u n n d d Westmead Hospital Page 2 2 This report was prepared by the National Breast Cancer Centre: 92 Parramatta Road Camperdown, Sydney, Australia Locked Bag 16 Camperdown NSW 1450 Telephone +61 2 9036 3030 Facsimile +61 2 9036 3077 Website www.nbcc.org.au The Ovarian Cancer Program is funded by the Australian Government Department of Health and ...

ovarian cancer Palliative care and ovarian cancer Dr Katherine Clark Sydney Central Area Health Service Contents: Updated definition of palliative care Why palliative care in ovarian cancer ? Background: The W.H.O originally defined palliative care in 1984 as an extension of its global initiative to improve cancer pain control Major focus of palliative care at this point was to improve end of life care, with emphasis placed on the care of patients not responding to therapy Increasing recognition that principles of palliative care should be applied as early as possible to any ultimately life-threatening disease Acknowledgement that pain relief is an important but by no means the only consideration in the care of these patients Re-definition of palliative care ...

CD24 Is Expressed in Ovarian Cancer and Is a New Independent Prognostic Marker of Patient Survival Glen Kristiansen,* Carsten Denkert,* Karsten Schlu¨ns,* Edgar Dahl, † Christian Pilarsky, † and Steffen Hauptmann* From the Institute of Pathology, * Charite´ Hospital, Berlin; and MetaGen Pharmaceuticals † , Berlin, Germany CD24 is a small heavily glycosylated glycosylphosphati- dylinositol-linked cell surface protein, which is ex- pressed in hematological malignancies as well as in a large variety of solid tumors. Very recently its expres- sion in ovarian cancer has been found on RNA level by chip analysis. We evaluated CD24 protein expression by immunohistochemistry in 9 normal ovaries and 69 ep- ithelial ovarian tumors (5 adenomas, 8 borderline tu- mors, and 56 carcinomas) with known follow-up data. ...

A fact sheet from the Greater Bay Area Cancer Registry Ovarian Cancer in the Greater San Francisco Bay Area 1990-2000 Spring 2004 Cancer of the ovary is the fifth most common cause of cancer death among women in California. Based on the latest state cancer registry figures, 504 women were diagnosed and 290 died from ovarian cancer during 2000 in the Greater San Francisco Bay Area. Ovarian cancer incidence and mortality in our region have decreased slightly in the last ten years. Between 1990 and 2000, incidence and mortality rates have decreased approxi- mately 1-2% per year (below, Figure 1). Figure 1. Age-adjusted incidence and mortality rates for ovarian cancer by year of diagnosis, Greater San Francisco Bay Area, 1990-2000 0 2 4 6 8 10 12 14 16 18 20 1990 1991 1992 ...

BRCA and Breast/ Ovarian Cancer -- Clinical Validity Version 2004-3 3-1 CLINICAL VALIDITY Question 20. Are there methods to resolve clinical false positive results in a timely manner? Clinical false positives are defined as women who carry a deleterious BRCA1/2 mutation and neither have breast or ovarian cancer nor will develop one of these cancers during their lifetime. As with most presymptomatic DNA testing, there are no methods to resolve clinical false positives among women identified with a mutation conveying increased susceptibility. If a woman has a BRCA1/2 mutation and has not developed breast and/or ovarian cancer by the time of testing, estimates of breast and ovarian cancer risks can be given based on age and family history. Preventive/risk-reducing measures can then be considered. However, there is currently no way of determining whether an individual ...

BRCA and Breast/ Ovarian Cancer -- Clinical Utility Version 2004-3 4-1 CLINICAL UTILITY Question 26: What is the natural history of the disorder? Question 27: What is the impact of a positive (or negative) test on patient care? Question 28: If applicable, are diagnostic tests available? Question 29: Is there an effective remedy or acceptable action, or other measurable benefit? Question 30: Is there general access to that remedy or action? Question 31: Is the test being offered to a socially vulnerable population? Question 32: What quality assurance measures are in place? Question 33: What are the results of pilot trials? Question 34: What health risks can be identified for follow-up testing and/or intervention. Question 35: What are the financial costs associated with testing? Question 36: What are the economic benefits associated with actions resulting from testing? Question ...

N A T I O N A L O V A R I A N C A N C E R C O A L I T I O N , I N C N A T I O N A L O V A R I A N C A N C E R C O A L I T I O N , I N C Our mission is to raise awareness about ovarian cancer and to promote education about this disease. By dispelling myths and misunderstandings, the Coalition is committed to improving the overall survival rate and quality of life for women with ovarian cancer . Our mission is to raise awareness about ovarian cancer and to promote education about this disease. By dispelling myths and misunderstandings, the Coalition is committed to improving the overall survival rate and quality of life for women with ovarian cancer . S p r i n g 2 0 0 4 / I s s u e N o . 1 8 Page 2 NATIONAL OVARIAN CANCER COALITION BOARD OF DIRECTORS Maria Ciesla, President Julene ...

ovarian cancer Epithelial Ovarian Cancer Treatment Nadine Soplop April 28, 2004 Outline of Therapy Epidemiology Conventional Treatment Method of enhancing apoptotic pathway with small molecule inhibitor Targeting of small molecule inhibitor Modifications of Therapy Flaws and Advantages Epidemiology Women have a 1/70 chance of getting ovarian cancer in their lifetime 24,000 cases of Ovarian Cancer are diagnosed annually Ovarian Cancer is responsible for 14,000 deaths annually Diagnosis usually determined to be Stage III/IV Conventional Treatments Combination chemotherapy: pacltaxel and cisplatin Surgery Radiation therapy With Stage III/IV diagnosis, 75% initial response, but 50% relapse within 3 ...

HEALTH INFORMATION YOU CAN TRUST Kathie Clark, RN, PhD CCN/C Co-Director Ovarian Cancer Plus ++ April 29, 2004 Page 2 The Canadian Cochrane Network and Centre Le Réseau-centre canadien Cochrane QUESTIONS 1. Do you have the time to read all the information you need read to to make the health decisions you need to make? 2. Do you know where to find the best available information? 3. Do you know how to evaluate the information once you have found it? Page 3 The Canadian Cochrane Network and Centre Le Réseau-centre canadien Cochrane WHO ARE YOU ? 1. Patients and consumers 2. Families and friends 3. Nurses and other health clinicians 4. Family doctors and specialists 5. Students Page 4 The Canadian Cochrane ...

National Ovarian Cancer Association For Immediate Release CELEBRATE THE WOMEN IN OUR LIVES GALA LUNCHEON - Features 25-year-old Ovarian Cancer Survivor - TORONTO, Wednesday, April 28, 2004 - The National Ovarian Cancer Association (NOCA) is holding its 3 rd Annual Gala Luncheon, "Celebrate the Women in our Lives," on Friday, May 14 th at the Toronto Marriott Eaton Centre. Hosted by broadcaster Jane Hawtin , the luncheon's keynote speaker will be Chatelaine's Rona Maynard , and feature Krystal Dorion , a 25-year-old survivor of ovarian cancer (below), and Dr. Lesa Dawson , a gynecologic oncologist from the Newfoundland Cancer Treatment Research Foundation. Founded in 1997, NOCA provides leadership by supporting women living with ovarian cancer and their families; raising awareness in the general public and ...

http://www.abc.net.au/news/newsitems/s1096601.htm ] Wine linked to lower ovarian cancer rate Queensland scientists believe having a daily glass of wine could reduce the risk of ovarian cancer . While ovarian cancer kills about 800 women in Australia each year, its cause is still largely unknown. But an Institute of Medical Research study shows women who drink wine have a lower risk of the cancer than non-drinkers and those who only drink beer or spirits. The institute’s Dr Penny Webb says women who drink more than one glass of red wine a day are almost seven times less likely to develop ovarian cancer than non-drinkers. “But it also suggested that perhaps it wasn’t the alcohol in the wine, because we saw no effect for beer and for spirits,” she said. “What we want to do now is look at this in a new study. “There does seem to be something about wine. The next question is ...

8th Annual Ovarian Cancer Survivors Retreat ~ for women who are currently undergoing or have completed treatment for ovarian cancer ~ This retreat will include: * workshops * resource information * fabulous food * great entertainment * guest speakers * recreational activities * beautiful cabins * making new friends * networking opportunities * art studio sessions * fireside chats * group discussions Registration fee is $150 per person (registration after July 31, 2004 goes up to $200). Cost includes all accommodations, meals, entertainment and on-site retreat activities. Transportation is not included. Attendees will be accepted on a first come, first serve basis up to a maximum of 56 participants. A portion of each registration fee has been underwritten by the Ovarian Cancer Survivors Foundation through the support of GlaxoSmithKline, ...

For more information: Inherited Breast and Ovarian Cancer Information for women attending the Family Cancer Clinic Last updated Nov 2001 Seen in clinic by. Who is at increased risk of inherited breast and ovarian cancer ? Women who may be at increased risk are those who have: - Either several close relatives on the same side of the family who have had breast and/or ovarian cancer , with at least one relative diagnosed before age 50. - Or at least one first degree relative (e.g. mother, sister, daughter) who has had breast cancer . What can you do if you are at increased risk? Sometimes we can do a blood test to find out if a person has inherited an altered BRCA1 or BRCA2 gene. The test is only possible if we find that somebody in the family who has had breast or ovarian cancer ...

102 Title 3—The President Proc. 7699 must make these programs available to more people. By providing vouchers that enable those struggling with addiction to get help from a wide range of sources that work, including faith-based and community organizations, we will expand treatment options and accountability. This flexibility will strengthen our system and offer more hope to those in need. My Administration has taken important steps to cut off illegal drug sup- plies and reduce demand through anti-drug education. For those who be- come addicted to drugs or to alcohol, my Administration is committed to tearing down the stigma attached to recovery so that more people will seek the help they need. Alcohol addiction and drug addiction are diseases that touch all Americans—young and old, rich and poor, male and female. As a Nation, we must continue our efforts to offer the best possible opportuni- ...

S um m e r 2 0 0 1 S um m e r 2 0 0 1 health health NEWS NEWS A WINNING NICU TEAM A WINNING NICU TEAM HOPE FOR Ovarian Cancer HOPE FOR Ovarian Cancer Y O U R S O U R C E F O R H E A LT H A N D M E D I C I N E Y O U R S O U R C E F O R H E A LT H A N D M E D I C I N E Meeting Epilepsy Challenges Page 2 x giving birth to twins or triplets x who have certain medical condi- tions, including pre-eclampsia, high blood pressure, diabetes with preterm labor, or premature rupture of the membranes. HELPING PREEMIES HAVE HEALTHY LUNGS Across the country, about 11% of babies weighing less than 2.2 pounds don’t sur- vive. But at GW over the past 16 months, all of these lizabeth White’s ...

New Jersey Oncologist Says Ovarian Cancer Test May Catch Diseas http://www.miami.com/mld/miamiherald/business/national/8430195.h 1 of 3 4/20/2004 12:23 PM Posted on Wed, Apr. 14, 2004 New Jersey Oncologist Says Ovarian Cancer Test May Catch Disease Early By Bob Groves, The Record, Hackensack, N.J. Knight Ridder/Tribune Business News Apr. 13 - A promising test for ovarian cancer is based on a new way of detecting disease that is as plain as the nose on your face, says a New Jersey oncologist who helped research the technique. OvaCheck could prove to be the first test to detect deadly ovarian cancer in its early stages, when it is most curable. The test could potentially save thousands of lives. The experimental test works by identifying patterns of abnormal proteins in a patient's blood, like picking out a face in the crowd, said Dr. Charles B. Simone of ...

Ovarian cancer often has no symptoms. Just ask Carolyn Logue. In 1994, she felt fine but her physician found ovarian cancer – the disease that had taken her sister’s life. Carolyn’s doctor referred her to Dr. Robert Burger at the Chao Family Comprehensive Cancer Center at UCI Medical Center. Dr. Burger and his team treated Carolyn’s disease with leading-edge therapies and a multifacted approach including surgery, chemotherapy and radiation. Today, Carolyn celebrates being a ten-year survivor. Not only does Carolyn proudly wear the title of cancer survivor, she is thrilled to be a wife, mother, grandmother and great-grandmother. To learn more or receive a physician referral, call toll free 1-877-UCI-DOCS or visit us online at www.ucihealth.com. UCI Medical Center is the only Orange County hospital ranked in U.S. News & World Report’s ® listing of “America’s ...

Questions and Answers: OvaCheck ™ and NCI/FDA Ovarian Cancer Clinical Trials Using Proteomics Technology 1. What is the National Cancer Institute/U.S. Food and Drug Administration Clinical Proteomics Program? The collaboration between the National Cancer Institute (NCI) and the U.S. Food and Drug Administration ( FDA) began in 1997, and is led by Lance Liotta, M.D. Ph.D., of NCI's Center for Cancer Research and Emanuel Petricoin, Ph.D., of FDA's Center for Biologics Evaluation and Research (CBER). The NCI/FDA clinical proteomics program ties the study of all proteins in living cells (or proteomics) to the clinical care of patients. Specific technologies developed in this program are at an early stage of application to diagnosis and treatment of cancer patients. The scientific goal of proteomics is to capture the information flow within the cell and the organism. Petricoin and Liotta ...

ovarian cancer FREE OVARIAN CANCER SCREENING Since early stage ovarian cancer is curable, effort is being made to detect this disease before it produces symptoms. The UK Ovarian Cancer Screening Program offers free screening to women living in Fleming County in Maysville at the Mason County Health Department located at 120 West 3rd Street in Maysville. This program is open to asymptomatic women who are at least 50 years of age or women over 25 years of age who can document that a close family member had ovarian cancer . To schedule an appointment, obtain information or evaluation, call 1-800-766-8279. Screening is free and utilizes state-of-the-art GE ultrasound technology. Women who are experiencing pelvic symptoms should contact their physician. For more information, go to http://clik.to/ovary For further information, call Donna ...

FY03 Ovarian Cancer Research Program Peer Reviewers Aldaz, Claudio M.D., Ph.D. Department of Carcinogenesis, UT MD Anderson Cancer Center Baker, Vicki M.D. Obstetrics and Gynecology Dept, Wayne State University Bar-Eli, Menashe Ph.D. Cancer Biology, UT MD Anderson Cancer Center Batra, Surinder Ph.D. Dept of Biochemistry and Molecular Biology, Univ of Nebraska Medical Ctr., Eppley Cancer Ctr Beattie, Craig Ph.D. Department of Animal Biotechnology, University of Nevada- Reno Beck, William Ph.D. Department of Biopharmaceutical Sciences, University of Illinois at Chicago Benbrook, Doris Ph.D. Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center Britten, Richard Ph.D. Department of Radiation Oncology, Eastern Virginia Medical School Cannon, ...

Although twelve years have passed since the untimely death of comedy's pint-size dynamo, Gilda Radner's legacy as a victim of ovarian cancer has brought greater focus to this silent disease. Ovarian cancer is one of the most common forms of gynecologic malignancies. According t the American Cancer Society, it is the fourth most frequent cause of cancer death. This year alone, over 25,000 women will be diagnosed with the disease, and about 14,000 will die. There are three major types of ovarian cancer . The first is epithelial carcinoma, which arises from the cells covering the surface of the ovaries. This accounts for 80% of all ovarian cancer cases. The second is germ cell tumors, which develops in the eggs. This is usually seen in a young woman, and is unfortunately very aggressive and fast growing. This type is often fatal within one to two years. The third is ovarian stromal tumors, ...

1998 1999 2001 2000 Fiscal Year Millions of Dollar s 2002 2003 $40.9M 0 20 40 60 80 100 120 $99.4M $93.5M $65.5M i $56.5M $76.9M Incidence and Mortality Rate Trends Ovarian cancer accounts for approximately four percent of all women’s cancers and is the fourth leading cause of cancer -related death among women. The incidence rate for ovarian cancer has been slowly declining since the early 1990s. Ovarian cancer has the highest mortality of all cancers of the female reproductive system, which reflects, in part, to a lack of early symptoms and proven ovarian cancer screening tests. Thus, ovarian cancer is often diagnosed at an advanced stage, after the cancer has spread beyond the ovary. ...

OVARIAN CANCER GROUP Our research interest is focused on the molecular aetiology of ovarian cancer . Previously we have shown that a region of chromosome 17q25.3 is commonly deleted in sporadic ovarian tumours, benign, borderline and malignant, and in all histological subtypes. At least 70% of malignant tumours have deletions involving this region and it remains the most common genetic abnormality detected in these tumours. This indicates that the gene which is the target of such deletions must play a key role in control of growth of normal ovarian epithelial cells. Other groups have shown that the same region is deleted in sporadic breast tumours. As a result of a positional cloning strategy, we have identified a new member of the septin gene family which we have named Ov/Br septin (recently renamed Sept9). Septins were first identified in screens for temperature sensitive mutations that ...

To find out more about ovarian cancer go to http://ovariancancer.jhmi.edu Dear : On September 16-19, 2004, I will be climbing in the HERA Ovarian Cancer Climb for Life to raise money for ovarian cancer research and to aide women and their families battling the disease. We are climbing for all the women battling this disease and the 25,500 women who will be newly diagnosed this year. I have committed to climbing __ feet and I have set a goal of raising money for this important cause. I am hoping to raise $__. Can I count on your support? The money raised will go directly to support research for early detection of ovarian cancer and new directions in treatment as well as to aide women and their families battling this disease and to support awareness and wellness programs. On the research front, our most pressing task is to develop a reliable early detection test for ovarian ...